Note: This document has been translated from the Japanese original for reference purposes only. In the event of any
discrepancy between this translated document and the Japanese original, the original shall prevail.

May 13, 2024

Consolidated Financial Results
for the Fiscal Year Ended March 31, 2024
(Under Japanese GAAP)
Company name:
Listing:
Securities code:
URL:
Representative:
Contact:

Paramount Bed Holdings Co., Ltd.
Tokyo Stock Exchange
7817
https://www.paramountbed-hd.co.jp
Tomohiko Kimura, President and Chief Executive Officer
Tatsuya Udagawa, General Manager, Finance Dept.
TEL: 03-3648-1100

Scheduled date of the ordinary general meeting of shareholders:
Scheduled date to commence dividend payments:
Scheduled date to file Securities Report:
Preparation of supplementary material on financial results:
Holding of financial results presentation meeting:June 27, 2024
June 10, 2024
June 27, 2024
Yes
Yes (for institutional investors andanalysts)(Millions of yen with fractional amounts discarded, unless otherwise noted)

1. Consolidated financial results for the fiscal year ended March 31, 2024 (from April 1, 2023 toMarch 31, 2024)(1) Consolidated operating results (cumulative)
Net sales
Fiscal year ended
March 31, 2024
March 31, 2023

Millions of yen

Operating profit% Millions of yen

106,016
99,009Note: Comprehensive income(Percentages indicate year-on-year changes.)

7.1
9.6

13,81813,452% Millions of yen

2.7
9.0

15,92014,139For the fiscal year ended March 31, 2024:
For the fiscal year ended March 31, 2023:

Basic earnings
per share

Diluted earnings
per share

Profit attributable toowners of parent

Ordinary profit% Millions of yen

12.6
4.4

10,622
9,215¥13,252 million¥9,432 million

Return on equity

%

15.3
1.3

[40.5%][(12.7)%]

Ratio of ordinary
Ratio of operating
profit to total
profit to net sales
assetsFiscal year ended

Yen

Yen

%

%

%

March 31, 2024

182.61

–

8.0

9.0

13.0

March 31, 2023

158.37

–

7.4

8.4

13.6

Reference:

Share of profit (loss) of entities accounted for using equity method
For the fiscal year ended March 31, 2024:¥– million
For the fiscal year ended March 31, 2023:¥– million

(2) Consolidated financial position
Total assets
As ofMarch 31, 2024
March 31, 2023
Reference:

Net assets

Equity-to-asset ratio

Net assets per share

Millions of yen

Millions of yen%

Yen

180,020
172,293

136,016
128,69775.6
74.7

2,368.78
2,207.86

Cash flows fromfinancing activities

Cash and cash
equivalents at end of
periodEquityAs of March 31, 2024:
As of March 31, 2023:¥136,015 million¥128,696 million(3) Consolidated cash flows
Cash flows fromoperating activities
Fiscal year ended
March 31, 2024
March 31, 2023

Cash flows frominvesting activities

Millions of yen

Millions of yen

7,521
9,151

(8,163)(6,332)Millions of yen

Millions of yen(5,969)(3,232)39,74045,663

2. Dividends
Annual dividends per share

Fiscal year ended

March 31, 2023
Fiscal year ended

March 31, 2024

Firstquarterend

Secondquarterend

Third
quarterend

Fiscalyear-end

Yen

Yen

Yen

Yen

–

28.00

–

31.00

59.00

–

31.00

–

34.00

65.00

–

48.00

–

49.00

97.00

Total

Ratio of
Payout ratio dividends to(Consolidated) net assets(Consolidated)

Total cash
dividends(Total)Yen Millions of yen

%

%

3,436

37.3

2.7

3,760

35.6

2.8

Fiscal year ending

March 31, 2025

55.1

(Forecast)

Note: The dividends forecasts for the fiscal year ending March 31, 2025 are calculated based on the new dividend policy.
For details, please refer to the “Notice Concerning Changes in Dividend Policy” released today.

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 toMarch 31, 2025)
Net sales

Six months ending
September 30,
2024
Fiscal year ending
March 31, 2025

(Percentages indicate year-on-year changes.)
Profit attributable to Basic earnings
Ordinary profit
owners of parent
per share

Operating profit

Millions ofyen%

51,0002.6

112,000

5.6

Millions ofyenMillions ofyen%Millions of
yen

%

Yen

5,200 (19.8)

5,450 (30.3)

3,850(27.3)

67.05

14,00014,50010,100(4.9)

175.90

%

1.3

(8.9)

* Notes(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in thechange in scope of consolidation): None
(2) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies in accordance with changes in accounting standards, etc.: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(3) Number of shares issued (common shares)(i)

Number of shares issued at the end of the period (including treasury shares)
As of March 31, 2024

61,754,974 shares

As of March 31, 2023

61,754,974 shares(ii) Number of treasury shares at the end of the period
As of March 31, 2024

4,334,941 shares

As of March 31, 2023

3,464,828 shares(iii) Average number of shares outstanding during the period
Fiscal year ended March 31, 2024

58,172,792 sharesFiscal year ended March 31, 2023

58,191,123 shares* Indication regarding execution of review procedures
The completion of review procedures in accordance with the Financial Instruments and Exchange Act is not
required for preparing this financial results report. At the time of disclosure of this financial results report, thereview procedures for consolidated financial statements in accordance with the Financial Instruments andExchange Act are incomplete.
* Proper use of earnings forecasts, and other special matters
The forward-looking statements, including earnings forecasts, contained in these materials are based on
information currently available to the Company and on certain assumptions deemed to be reasonable.
Consequently, the statements herein do not constitute assurances regarding the Company’s actual results. Actual
financial and other results may differ substantially from the statements herein due to various factors. Please refer
to “1. Overview of operating results and others, (1) Overview of operating results during the fiscal year underreview” on page 2 of the attached materials for the suppositions that form the assumptions for the earnings
forecasts and cautions regarding the use of the earnings forecasts.

Paramount Bed Holdings Co., Ltd. (7817)

Contents of Attached Materials
Index
1. Overview of operating results and others ................................................................................................. 2(1) Overview of operating results during the fiscal year under review .................................................... 2(2) Overview of financial position of the fiscal year under review.......................................................... 3
2. Basic concept regarding selection of accounting standards ...................................................................... 5
3. Consolidated financial statements and significant notes thereto............................................................... 6(1) Consolidated balance sheet ................................................................................................................ 6(2) Consolidated statement of income and consolidated statement of comprehensive income ............... 8
Consolidated statement of income...................................................................................................... 8
Consolidated statement of comprehensive income ............................................................................ 9(3) Consolidated statement of changes in equity ................................................................................... 10(4) Consolidated statement of cash flows .............................................................................................. 12(5) Notes to consolidated financial statements ....................................................................................... 14
Notes on premise of going concern .................................................................................................. 14
Segment Information, etc. ................................................................................................................ 14
Per share information ....................................................................................................................... 14
Significant subsequent events........................................................................................................... 14-1-

Paramount Bed Holdings Co., Ltd. (7817)

1. Overview of operating results and others(1) Overview of operating results during the fiscal year under review(i) Operating results during the fiscal year under review
During the fiscal year ended March 31, 2024, the Japanese economy continued to gradually recover,with the easing of various restrictions related to COVID-19 infections and the resulting progress innormalization of social and economic activities.
For the Group, the fiscal year ended March 31, 2024 is the final year of Phase I of the medium-term
management plan based on “Paramount Vision 2030,” which describes the type of company we aim to
be in 2030. We promoted initiatives for the key measures of Phase I, “expansion of current business,”“fully engaging in health promotion business,” and “establishing the foundations for change.”
In terms of operating results of our three core businesses, net sales in the medical care businessincreased by 9.1% year-on-year to ¥40,690 million, mainly due to the continuation of the steady
expansion of recurring revenue business in Japan and higher overseas sales year-on-year. In the nursing
care business, net sales increased by 6.7% year-on-year to ¥61,350 million, mainly due to efforts to
expand sales of the “Nemuri SCAN” body motion sensor, used mainly for monitoring applications in
nursing homes, and to enhance the lineup of various assistive products for home care, and by focusing
on the expansion of the rental wholesale business for assistive products. In the health promotion
business, net sales decreased by 12.2% year-on-year to ¥2,210 million, due mainly to changes in
consumer behavior following the downgrading of COVID-19 to a Class 5 disease, which resulted in aslump in visitors to retail stores.
In the area of product and service development, on October 2, 2023, we launched the “Nemuri
CONNECT” monitoring support system, which enables management of information detected by the“Nemuri SCAN” in the cloud. As of March 31, 2024, there were 177 facilities under contract. By
supporting to realize DX in the nursing care field, we aim to contribute to enhancements in nursing carequality and reductions in workload.
As for topics of the nursing care business, Paramount Care Service Co., Ltd., which operates a rental
wholesale business for assistive products, entered into an agreement on February 5, 2024, with SMFL
Rental Company, Limited (Chiyoda-ku, Tokyo; hereinafter “SMFL Rental”), which conducts a rental
wholesale business as an agent for Paramount Care Service Co., Ltd., under which Paramount Care
Service Co., Ltd. is to acquire on July 1, 2024 all of the shares of a new company that was establishedby SMFL Rental in conjunction with SMFL Rental splitting off its rental wholesale business. We aim tofurther expand our business, such as by consolidating operations in areas where we have been
franchising.
The information on disaggregation of net sales for the fiscal year ended March 31, 2024 is as follows.
Net sales by business(Millions of yen)
Sales categories

Fiscal year ended March 31,
2023

Fiscal year ended March 31,
2024

ChangeMedical care

37,291

40,690

9.1%

Nursing care

57,521

61,350

6.7%

Health promotion

2,517

2,210

(12.2)%

Others

1,678

1,764

5.1%

Total

99,009106,016

7.1%-2-

Paramount Bed Holdings Co., Ltd. (7817)

Net sales by region(Millions of yen)
Sales categories

Fiscal year ended March 31,
2023

Fiscal year ended March 31,
2024

ChangeDomestic

89,73895,411

6.3%

Overseas

9,271

10,605

14.4%

Total

99,009106,016

7.1%

As a result of the above, net sales for the fiscal year under review increased by ¥7,007 million (up7.1%) year-on-year to ¥106,016 million, operating profit increased by ¥365 million (up 2.7%) to¥13,818 million, ordinary profit increased by ¥1,781 million (up 12.6%) to ¥15,920 million mainly due
to the recording of foreign exchange gains, and profit attributable to owners of parent increased by¥1,407 million (up 15.3%) to ¥10,622 million.
As the Group’s business consists of a single segment, segment information has been omitted.
(ii) Future Outlook
As for the future outlook, although further normalization of economic activity is expected, the outlook
remains uncertain due to labor shortages resulting from reforms in work styles, inflation concerns, andheightened geopolitical risks.
On April 1, 2020, we formulated “Paramount Vision 2030,” which describes the type of company we
aim to be in 2030. Under the slogan of “Smiles for everyone, from medical care and nursing care to
health,” we aim to contribute to everyone in the field of health as well, based on the technologies andknowledge we have cultivated over the years in the medical and nursing care fields. In April 2024, themedium-term management plan based on this vision moved into Phase II (final year: fiscal year ending
March 31, 2027). By focusing on the priority measures of “expansion of recurring business,”“evolution of health promotion business,” and “rapid growth in focused areas in Asia,” the Group aims
to achieve ¥120,000 million in net sales and ¥17,000 million in operating profit which are the targets
for the fiscal year ending March 31, 2027. For details of Phase II of our medium-term management
plan, please refer to the “Notice Concerning Medium-Term Management Plan” released today.
For the next fiscal year, we forecast net sales of ¥112,000 million (up 5.6% from the current fiscal
year), operating profit of ¥14,000 million (up 1.3%), ordinary profit of ¥14,500 million (down 8.9%),
and profit attributable to owners of parent of ¥10,100 million (down 4.9%).
(2) Overview of financial position of the fiscal year under review(i) Assets, liabilities and net assets
Total assets at the end of the current fiscal year increased by ¥7,726 million compared with the end of
the previous fiscal year, and stood at ¥180,020 million. The main aspects that contributed to thisincrease were increases in notes and accounts receivable - trade and investment securities.
Liabilities increased by ¥407 million compared with the end of the previous fiscal year, and stood at¥44,004 million. The main aspects that contributed to this increase were increases in lease liabilities,
and retirement benefit liability.
Net assets increased by ¥7,319 million compared with the end of the previous fiscal year, and stood at¥136,016 million. The main aspects that contributed to this increase were increases in retained
earnings, and foreign currency translation adjustment.
As a result of the above, equity-to-asset ratio rose by 0.9 points, compared with the end of the previous
fiscal year to 75.6%.

-3-

Paramount Bed Holdings Co., Ltd. (7817)(ii) Cash flows
Cash and cash equivalents (hereinafter called “cash”) stood at ¥39,740 million at the end of the current
fiscal year. The respective cash flows and their causes during the fiscal year under review, are as
follows.
Cash flows from operating activities
Net cash provided by operating activities amounted to ¥7,521 million. This was mainly due to anincrease in cash from profit before income taxes of ¥15,500 million and depreciation of ¥9,765 million,
despite an increase in rental assets of ¥7,717 million due to the expansion of recurring revenue businessand an increase in trade receivables of ¥5,144 million.
Cash flows from investing activities
Net cash used in investing activities amounted to ¥8,163 million. This was mainly due to a decrease in
cash from purchase of long-term investment securities of ¥4,441 million, purchase of property, plantand equipment of ¥2,853 million mainly for renewal of painting facilities of factory in PT. Paramount
Bed Indonesia, purchase of intangible assets of ¥1,382 million for Enterprise Resource Planning systemand others, despite an inflow from proceeds from sale of securities of ¥1,579 million, etc.
Cash flows from financing activities
Net cash used in financing activities amounted to ¥5,969 million. This was mainly due to a decrease in
cash from dividends paid of ¥3,615 million and purchase of treasury shares of ¥2,399 million.
(Reference) Trends in cash flow-related indicators
Fiscal year ended
March 31, 2022

Fiscal year ended
March 31, 2023

Fiscal year ended
March 31, 2024

Equity ratio (%)

74.1

74.7

75.6

Equity ratio based on market value (%)

70.6

79.8

83.1

Ratio of interest-bearing debt to cash flow (%)

81.0

62.4

82.0

Interest coverage ratio (times)

87.9

97.3

63.6

Equity ratio: equity/total assets
Equity ratio based on market value: market capitalization/total assets
Ratio of interest-bearing debt to cash flow: interest-bearing debt/cash flow from operating activities
Interest coverage ratio: operating cash flows/interest payments
1. Each indicator is calculated based on consolidated financial indicators.
2. Market capitalization is calculated by multiplying the closing share price at the end of the fiscal yearby the number of shares issued (after deducted treasury shares) at the end of the fiscal year.
3. Interest-bearing debt covers all liabilities on which interest has been paid among liabilities recordedin the consolidated balance sheet.
4. Operating cash flows represents cash flows from operating activities in the consolidated statementof cash flows. For interest payments, interest paid in the consolidated statement of cash flows is
used.

-4-

Paramount Bed Holdings Co., Ltd. (7817)

2. Basic concept regarding selection of accounting standards
Taking into account the comparability of consolidated financial statements over the period and thecomparability between companies, the Group intends, for the time being, to prepare consolidated
financial statements based on Japanese accounting standards.
With respect to adoption of international financial reporting standards (IFRS), the Group follows apolicy of responding in a suitable manner after giving consideration to various circumstances in Japanand overseas.

-5-

Paramount Bed Holdings Co., Ltd. (7817)

3. Consolidated financial statements and significant notes thereto(1) Consolidated balance sheet(Millions of yen)
As of March 31, 2023
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade
Lease receivables and investments in leases
Securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Income taxes refund receivable
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Land
Leased assets
Accumulated depreciation
Leased assets, net
Assets for rent
Accumulated depreciation
Assets for rent, net
Construction in progress
Other
Accumulated depreciation
Other, net
Total property, plant and equipment
Intangible assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets-6-

As of March 31, 2024

39,82024,793
5,526
13,412
8,233
362
2,660
336
2,072
(83)
97,13533,82830,382
6,525
12,918
7,069
397
2,729
–
1,730
(84)
95,49632,171(22,617)
9,553
9,440
(8,068)
1,371
8,846
2,652
(1,428)
1,223
52,976(32,245)
20,731579
10,682(9,409)1,273
43,57933,165(23,401)
9,764
9,716
(8,378)
1,337
8,846
2,680
(1,201)
1,478
57,849(35,998)
21,851
562
11,986(10,156)
1,829
45,670

4,344
4,344

4,800
4,800

18,244
3,894
5,925
(830)
27,23475,158172,293

23,063
4,272
7,349
(631)
34,052
84,523
180,020

Paramount Bed Holdings Co., Ltd. (7817)(Millions of yen)
As of March 31, 2023
Liabilities
Current liabilities
Notes and accounts payable - trade
Lease liabilities
Income taxes payable
Provision for bonuses
Provision for bonuses for directors (and otherofficers)
Other
Total current liabilities
Non-current liabilities
Lease liabilities
Deferred tax liabilities
Retirement benefit liability
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets-7-

As of March 31, 2024

13,432
1,542
2,410
1,647

12,185
1,362
2,678
1,740

28

24

7,239
26,300

6,905
24,897

3,965
5,709
7,005
615
17,296
43,596

4,602
6,512
7,484
507
19,10644,004

4,207
51,902
76,338(6,742)
125,705

4,207
51,91883,346(9,077)130,394

889
2,400
(299)
2,990
0
128,697
172,293

1,903
3,894
(177)
5,620
0
136,016
180,020

Paramount Bed Holdings Co., Ltd. (7817)(2) Consolidated statement of income and consolidated statement of comprehensive income
Consolidated statement of income(Millions of yen)
Fiscal year ended
March 31, 2023
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Insurance claim income
Foreign exchange gains
Gain on investments in silent partnerships
Gain on investments in investment partnerships
Gain on sale of scraps
Other
Total non-operating income
Non-operating expenses
Interest expenses
Provision of allowance for doubtful accounts
Loss on investments in investment partnerships
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of investment securities
Gain on redemption of investment securities
Settlement income
Total extraordinary income
Extraordinary losses
Loss on redemption of investment securities
Loss on valuation of investment securities
Loss on valuation of shares of subsidiaries andassociates
Total extraordinary losses
Profit before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
ProfitProfit attributable to non-controlling interests
Profit attributable to owners of parent-8-

Fiscal year ended
March 31, 2024

99,00951,80647,202
33,74913,452106,016
55,38450,63236,813
13,818

197
203
74
484
–
–
75
221
1,257

397
290
14
1,367
89
33
68
168
2,430

94
375
33
67
570
14,139

118
175
–
34
328
15,920

–
89
153
242

10
73
–
84

2
173

8
10

392

485

568
13,812
4,560
35
4,596
9,215
0
9,215

504
15,500
4,946
(68)
4,877
10,6220
10,622

Paramount Bed Holdings Co., Ltd. (7817)

Consolidated statement of comprehensive income(Millions of yen)
Fiscal year ended
March 31, 2023
ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners ofparentComprehensive income attributable to non-controllinginterests-9-

Fiscal year ended
March 31, 2024

9,215

10,622

(663)
961
(81)
217
9,432

1,014
1,493
121
2,630
13,252

9,432

13,25200Paramount Bed Holdings Co., Ltd. (7817)(3) Consolidated statement of changes in equity
Previous fiscal year (April 1, 2022 to March 31, 2023)(Millions of yen)
Shareholders’ equity

Balance at beginning of period

Share capital

Capital surplus

Retainedearnings

Treasury shares

Total
shareholders’equity4,207

51,822

69,889(7,017)

118,901

Changes during period
Dividends of surplus(3,315)(3,315)

Profit attributable to owners ofparent

9,215

9,215

464

464

Change in scope of
consolidation
Purchase of treasury shares
Disposal of treasury shares

79

Transfer from accumulated
other comprehensive income toretained earnings

(0)

(0)

276

355

85

85

Net changes in items otherthan shareholders’ equity
Total changes during period
Balance at end of period

–

79

6,449

275

6,804

4,207

51,902

76,338(6,742)

125,705

Accumulated other comprehensive income

Balance at beginning of period

Valuationdifference on
available-forsale securities

Foreigncurrencytranslation
adjustment

1,552

1,438

Remeasurementsof defined
benefit plans
(218)

Total
accumulated
othercomprehensive
income2,773

Noncontrollinginterests

0

Total net assets

121,675

Changes during period
Dividends of surplus(3,315)

Profit attributable to owners ofparent9,215

Change in scope of
consolidation

464

Purchase of treasury shares(0)

Disposal of treasury shares

355

Transfer from accumulated
other comprehensive income toretained earnings

85

Net changes in items otherthan shareholders’ equity

(663)

961

(81)

217

0

217

Total changes during period

(663)

961

(81)

217

0

7,022

Balance at end of period

889

2,400

(299)

2,990

0

128,697- 10 -

Paramount Bed Holdings Co., Ltd. (7817)

Current fiscal year (April 1, 2023 to March 31, 2024)(Millions of yen)
Shareholders’ equity

Balance at beginning of period

Share capital

Capital surplus

Retainedearnings

Treasury shares

Total
shareholders’equity4,207

51,902

76,338(6,742)

125,705

Changes during period
Dividends of surplus(3,614)(3,614)

Profit attributable to owners ofparent10,622

10,622

Purchase of treasury shares
Disposal of treasury shares

16(2,399)(2,399)64

80

Net changes in items otherthan shareholders’ equity
Total changes during period
Balance at end of period

–

16

7,007

(2,334)

4,689

4,207

51,91883,346(9,077)130,394

Accumulated other comprehensive income

Balance at beginning of period

Valuationdifference on
available-forsale securities

Foreigncurrencytranslation
adjustment

Remeasurementsof defined
benefit plans

Total
accumulated
othercomprehensive
incomeNoncontrollinginterests

Total net assets

889

2,400

(299)

2,990

0

128,697

Changes during period
Dividends of surplus(3,614)

Profit attributable to owners ofparent10,622

Purchase of treasury shares(2,399)

Disposal of treasury shares80

Net changes in items otherthan shareholders’ equity

1,014

1,493

121

2,630

0

2,630

Total changes during period

1,014

1,493

121

2,630

0

7,319

Balance at end of period

1,903

3,894

(177)

5,620

0

136,016- 11 -

Paramount Bed Holdings Co., Ltd. (7817)(4) Consolidated statement of cash flows(Millions of yen)
Fiscal year ended
March 31, 2023
Cash flows from operating activities
Profit before income taxes
Depreciation
Amortization of goodwill
Increase (decrease) in provision for bonuses
Increase (decrease) in retirement benefit liability
Increase (decrease) in allowance for doubtful accounts
Interest and dividend income
Foreign exchange losses (gains)
Insurance claim income
Interest expenses
Loss (gain) on investments in investment partnerships
Loss (gain) on investments in silent partnerships
Loss (gain) on sale of short-term and long-term
investment securities
Loss (gain) on valuation of investment securities
Loss on valuation of shares of subsidiaries andassociates
Decrease (increase) in trade receivables
Net decrease (increase) in lease receivables andinvestments in leases
Increase in assets for rent
Decrease (increase) in inventories
Increase (decrease) in trade payables
Payments for lease liabilities
Other, net
SubtotalInterest and dividends received
Interest paid
Income taxes refund
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchase of securities
Proceeds from sale of securities
Purchase of property, plant and equipment
Purchase of intangible assets
Purchase of investment securities
Proceeds from sale of investment securities
Purchase of shares of subsidiaries and associates
Proceeds from distribution of investment partnerships
Purchase of insurance funds
Proceeds from maturity of insurance funds
Loan advances
Other, net
Net cash provided by (used in) investing activities- 12 -

Fiscal year ended
March 31, 2024

13,812
8,482
57
21
198
345
(401)
(86)
(74)
94
33
13

15,500
9,765
–
84
440
(207)
(687)
(377)
(14)
118
(33)
(89)

(86)

(75)

173

10

392

485

(753)

(5,144)(469)(1,008)(8,005)(968)
96(1,670)1,620
12,825394(94)
711(4,685)
9,151(7,717)
1,314(1,367)(1,415)
1,844
11,424
630
(118)
452
(4,867)
7,521

(500)
1,994
(1,814)(1,988)(2,898)905(1,523)
177
(369)
123
(457)
17
(6,332)

(500)
1,579
(2,853)(1,382)(4,441)
605
(386)
236
(97)
70
(1,790)795(8,163)

Paramount Bed Holdings Co., Ltd. (7817)(Millions of yen)
Fiscal year ended
March 31, 2023
Cash flows from financing activities
Purchase of treasury shares
Dividends paid
Other, net
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Increase in cash and cash equivalents resulting from
inclusion of subsidiaries in consolidation
Cash and cash equivalents at end of period- 13 -

Fiscal year ended
March 31, 2024

(0)(3,321)89(3,232)(2,399)(3,615)45(5,969)

419

688

7
45,462(5,922)
45,663

194–

45,66339,740Paramount Bed Holdings Co., Ltd. (7817)(5) Notes to consolidated financial statements
Notes on premise of going concern
Not applicable.
Segment Information, etc.
Segment Information
Previous fiscal year (April 1, 2022 to March 31, 2023)
As the Group’s business consists of a single segment of healthcare-related business, segment
information has been omitted.
Current fiscal year (April 1, 2023 to March 31, 2024)
As the Group’s business consists of a single segment of healthcare-related business, segment
information has been omitted.
Per share information(Yen)
Previous fiscal year (April 1,
2022 to March 31, 2023)
Net assets per share
Basic earnings per share

Current fiscal year (April 1,
2023 to March 31, 2024)

2,207.86

2,368.78

158.37

182.61

Notes: 1. Diluted earnings per share is not shown because there are no residual shares with dilutive effects.
2. The basis for calculating basic earnings per share is as follows.
Previous fiscal year (April 1,
2022 to March 31, 2023)
Basic earnings per share
Profit attributable to owners of parent (Millions ofyen)Amount not attributable to common shareholders(Millions of yen)
Profit attributable to owners of parent relating toordinary shares (Millions of yen)
Average number of shares during the period (shares)

Significant subsequent events
Not applicable.

- 14 -

Current fiscal year (April 1,
2023 to March 31, 2024)

9,215

10,622

–

–

9,215

10,62258,191,123

58,172,792